Age affects drug survival rates of interleukin (IL)‐17 and IL‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study
Andrea Chiricozzi,Giulia Coscarella,Luis Puig,Ron Vender,Jensen Yeung,José‐Manuel Carrascosa,Stefano Piaserico,Paolo Gisondi,Charles Lynde,Paulo Ferreira,Pedro Mendes Bastos,Esteban Dauden,Luiz Leite,Joana Valerio,Elena del Alcázar‐Viladomiu,Eva Vilarrasa,Mar Llamas‐Velasco,Mario Alessandri‐Bonetti,Francesco Messina,Manfredo Bruni,Eugenia Veronica Di Brizzi,Federica Ricceri,Alessia Nidegger,Jan Hugo,Asfandyar Mufti,Athina‐Ioanna Daponte,Laetitia Teixeira,Anna Balato,Marco Romanelli,Francesca Prignano,Spyridon Gkalpakiotis,Curdin Conrad,Elizabeth Lazaridou,Natalia Rompoti,Alexander J. Stratigos,Miguel Nogueira,Ketty Peris,Tiago Torres
DOI: https://doi.org/10.1111/jdv.20143
2024-06-12
Journal of the European Academy of Dermatology and Venereology
Abstract:Background Scarce data related to the drug survival of biologic agents in psoriasis patients aged ≥65 years is available. Objectives To evaluate the drug survival of interleukin (IL)‐23 or the IL‐17 inhibitors approved for the treatment of moderate‐to‐severe psoriasis in elderly patients (aged ≥65 years), compared with younger adult patients (aged <65 years), and to identify clinical predictors that can influence the drug survival. Methods This retrospective multicentric cohort study included adult patients with moderate‐to‐severe psoriasis, dissecting two‐patient subcohorts based on age: elderly versus younger adults. Kaplan–Meier estimator and proportional hazard Cox regression models were used for drug survival analysis. Results We included 4178 patients and 4866 treatment courses; 934 were elderly (1072 treatment courses), and 3244 were younger patients (3794 treatment courses). Drug survival, considering all causes of interruption, was higher in patients aged <65 years than in elderly patients overall (log‐rank p
dermatology